A chemo-free tumor microenvironment (TME) reshaping regimen combining glofitamab induces a high CR rate in relapsed/refractory diffuse large B cell lymphoma (DLBCL)
Phase 2 trial demonstrates enhanced CR rates in R/R DLBCL using a combo of glofitamab, radiotherapy, and GM-CSF.
Key Points
To evaluate the efficacy of a chemo-free regimen combining glofitamab with radiotherapy and GM-CSF in enhancing treatment response in R/R DLBCL patients.
Single center, open label, investigator-initiated phase 2 trial with 22 patients enrolled.
Patients received glofitamab alongside large fraction radiotherapy, GM-CSF, and lenalidomide over 6 cycles.
T-cell function assessed by flow cytometry.
Primary endpoint was the CR rate by Lugano 2014 criteria.
11 patients enrolled with 100% achieving CR after the third cycle by the data cut-off.
Median patient age was 70 years; 54% had advanced Ann Arbor stage III/IV disease.
Safety evaluations showed 45% of patients experienced CRS events; all events resolved by data cut-off.